Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 209 people in the active treatment group (receiving a combination of sofosbuvir and ribavirin, referred to here as SOF+RBV) and 71 people in a placebo group (receiving dummy treatment). The trial was measuring whether people with hepatitis C could reach a point where the hepatitis C virus became undetectable in their blood — first at 4 weeks, then at 12 weeks, and again at 24 weeks after finishing treatment. The trial also tracked whether the virus came back during or after treatment, and whether any participants had to permanently stop taking the study drug due to unwanted side effects. The reported data shows that among those who received SOF+RBV, 78% had undetectable levels of the hepatitis C virus in their blood 12 weeks after finishing treatment (the main goal of the trial), compared with 0% in the placebo group. At 4 weeks after treatment, the reported figure for the SOF+RBV group was 83.1%, and at 24 weeks it was 77.8% — again, 0% for the placebo group at both timepoints. The reported data shows that 0% of participants in either group experienced what is called "viral breakthrough" (the virus becoming detectable again while still on treatment). However, a viral relapse rate of 20.5% was reported for the SOF+RBV group, meaning roughly 1 in 5 people in that group who had undetectable virus at the end of treatment saw the virus return afterwards. Regarding permanent stops due to unwanted effects, the reported data shows 1 participant in the SOF+RBV group and 0 in the placebo group stopped for this reason (from the 202 and 68 participants respectively assessed for this measure). These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 25040192) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Hepatitis C Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with Hepatitis C virus (HCV), specifically type 2 or type 3.
- You have been assessed and found to have cirrhosis (scarring of the liver).
- You are either unwilling to take interferon treatment, medically unable to take interferon treatment, or have previously tried interferon and could not tolerate it.
- Your blood test results from screening fall within the acceptable ranges set by the trial.
- You have not taken any experimental medication or used any experimental medical device in the 30 days before your screening visit.
- If you are a woman who could become pregnant, or a sexually active man, you are willing to use highly effective birth control methods during the trial.
Who may not be able to join:
- You have previously taken a specific type of Hepatitis C treatment that directly targets a part of the virus called NS5B (confirm with trial site if unsure whether your previous treatment applies).
- You are currently pregnant, breastfeeding, or are a man whose partner is pregnant.
- You have a history of serious liver failure or your liver has stopped functioning properly at any point (confirm with trial site).
- You have a significant ongoing or past illness or major health condition that could interfere with your treatment, the assessments, or your ability to follow the trial plan.
- You drink excessive amounts of alcohol or have a significant problem with substance misuse.
⚠️ Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
4 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Percentage of Participants Achieving SVR12; Number of Participants Experiencing Adverse Events Leading to Permanent Discontinuation of Study Drug
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.